Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

被引：6

作者：

Caldwell, Timothy M. ^{[1
]}

Kaufman, Michael D. ^{[1
]}

Wise, Scott C. ^{[1
]}

Ahn, Yu Mi ^{[1
]}

Hood, Molly M. ^{[1
]}

Lu, Wei -Ping ^{[1
]}

Patt, William C. ^{[1
]}

Samarakoon, Thiwanka ^{[1
]}

Vogeti, Lakshminarayana ^{[1
]}

Vogeti, Subha ^{[1
]}

Yates, Karen M. ^{[1
]}

Bulfer, Stacie L. ^{[1
]}

Le Bourdonnec, Bertrand ^{[1
]}

Smith, Bryan D. ^{[1
]}

Flynn, Daniel L. ^{[1
,2
]}

机构：

[1] Deciphera Pharmaceut LLC, Waltham, MA 02451 USA

[2] 643 Massachusetts St,Suite 200, Lawrence, KS 66044 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2022年 / 74卷

关键词：

CSF1R; Kinase; Acyl ureas; Cancer; TUMOR-ASSOCIATED MACROPHAGES; STIMULATING FACTOR-I; MICROGLIAL PROLIFERATION;

D O I：

10.1016/j.bmcl.2022.128929

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Based on the structure of an early lead identified in Deciphera's proprietary compound collection of switch control kinase inhibitors and using a combination of medicinal chemistry guided structure activity relationships and structure-based drug design, a novel series of potent acyl urea-based CSF1R inhibitors was identified dis-playing high selectivity for CSF1R versus the other members of the Type III receptor tyrosine kinase (RTK) family members (KIT, PDGFR-alpha, PDGFR-beta, and FLT3), VEGFR2 and MET. Based on in vitro biology, in vitro ADME and in vivo PK/PD studies, compound 10 was selected as an advanced lead for Deciphera's CSF1R research program.

引用

页数：6

共 24 条

[11] Tumour-associated macrophages as treatment targets in oncology [J].

Mantovani, Alberto ;

Marchesi, Federica ;

Malesci, Alberto ;

Laghi, Luigi ;

Allavena, Paola .

NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (07) :399-416

[12] Dynamic architecture of a protein kinase [J].

McClendon, Christopher L. ;

Kornev, Alexandr P. ;

Gilson, Michael K. ;

Taylora, Susan S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (43) :E4623-E4631

[13] The M-CSF receptor in osteoclasts and beyond [J].

Mun, Se Hwan ;

Park, Peter Sang Uk ;

Park-Min, Kyung-Hyun .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (08) :1239-1254

[14] Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability [J].

Murga-Zamalloa, Carlos ;

Rolland, Delphine C. M. ;

Polk, Avery ;

Wolfe, Ashley ;

Dewar, Hiran ;

Chowdhury, Pinki ;

Onder, Ozlem ;

Dewar, Rajan ;

Brown, Noah A. ;

Bailey, Nathanael G. ;

Inamdar, Kedar ;

Lim, Megan S. ;

Elenitoba-Johnson, Kojo S. J. ;

Wilcox, Ryan A. .

CLINICAL CANCER RESEARCH, 2020, 26 (03) :690-703

[15] Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration [J].

Neal, Matthew L. ;

Fleming, Sheila M. ;

Budge, Kevin M. ;

Boyle, Alexa M. ;

Kim, Chunki ;

Alam, Gelareh ;

Beier, Eric E. ;

Wu, Long-Jun ;

Richardson, Jason R. .

FASEB JOURNAL, 2020, 34 (01) :1679-1694

[16] Tumor-Associated Macrophages: From Mechanisms to Therapy [J].

Noy, Roy ;

Pollard, Jeffrey W. .

IMMUNITY, 2014, 41 (01) :49-61

[17] Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology [J].

Olmos-Alonso, Adrian ;

Schetters, Sjoerd T. T. ;

Sri, Sarmi ;

Askew, Katharine ;

Mancuso, Renzo ;

Vargas-Caballero, Mariana ;

Holscher, Christian ;

Perry, V. Hugh ;

Gomez-Nicola, Diego .

BRAIN, 2016, 139 :891-907

[18] Trophic macrophages in development and disease [J].

Pollard, Jeffrey W. .

NATURE REVIEWS IMMUNOLOGY, 2009, 9 (04) :259-270

[19] PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma [J].

Pollari, Marjukka ;

Bruck, Oscar ;

Pellinen, Teijo ;

Vahamurto, Pauli ;

Karjalainen-Lindsberg, Marja-Liisa ;

Mannisto, Susanna ;

Kallioniemi, Olli ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Mustjoki, Satu ;

Leivonen, Suvi-Katri ;

Leppa, Sirpa .

HAEMATOLOGICA, 2018, 103 (11) :1908-1914

[20] Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants [J].

Smith, Bryan D. ;

Kaufman, Michael D. ;

Lu, Wei-Ping ;

Gupta, Anu ;

Leary, Cynthia B. ;

Wise, Scott C. ;

Rutkoski, Thomas J. ;

Ahn, Yu Mi ;

Al-Ani, Gada ;

Bulfer, Stacie L. ;

Caldwell, Timothy M. ;

Chun, Lawrence ;

Ensinger, Carol L. ;

Hood, Molly M. ;

McKinley, Arin ;

Patti, William C. ;

Ruiz-Soto, Rodrigo ;

Su, Ying ;

Telikepalli, Hanumaiah ;

Town, Ajia ;

Turner, Benjamin A. ;

Vogeti, Lakshminarayana ;

Vogeti, Subha ;

Yates, Karen ;

Janku, Filip ;

Razak, Albiruni Ryan Abdul ;

Rosen, Oliver ;

Heinrich, Michael C. ;

Flynn, Daniel L. .

CANCER CELL, 2019, 35 (05) :738-+

← 1 2 3 →